BRUKINSA® (Zanubrutinib)

February 18, 2022February 18, 2022 RR FDA Approvals

The FDA on August 31, 2021, approved BRUKINSA® for adult patients with Waldenström’s Macroglobulinemia (WM). BRUKINSA® is a product of BeiGene.

Related Posts: